Merck & Co’s immuno-oncology drug Keytruda (pembrolizumab) is projected to be the best-selling drug by annual revenue in 2023, earning $22.2 billion by 2025, according to new research by GlobalData.
Commissions do not affect our editors' opinions or evaluations. No single credit card is the best option for every family, purchase or budget, but our credit cards editorial team set out to crunch ...